PRSS3 and gastric cancer: Mutations in PTEN (94%), ZNRF3 (94%), HLA-B (69%), MUC16 (69%), MST1L (69%), SOX4 (69%), ZFHX3 (69%), FOX1 (56%), PRSS3 (56%), BRD4 (50%), and TUBB2A (50%) were the most frequent alterations among the 16 patients with GC (Figure 3A).